Lancet-话题@MedSci

#Lancet#

4376篇内容 | 10448人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1831443, encodeId=9b041831443ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Respir Med：近期哮喘发作患者感染COVID-19后发生不良结局的风险加大, objectType=article, longId=294159, objectId=17f129415979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17f129415979, replyNumber=0, likeNumber=82, createdTime=2022-06-12, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17f129415979, moduleTitle=Lancet Respir Med：近期哮喘发作患者感染COVID-19后发生不良结局的风险加大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17f129415979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831211, encodeId=327f1831211e4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！, objectType=article, longId=212814, objectId=199e212814dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=199e212814dc, replyNumber=0, likeNumber=81, createdTime=2022-05-31, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=199e212814dc, moduleTitle=Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=199e212814dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831540, encodeId=607c18315409e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响, objectType=article, longId=724219, objectId=adc4e2421902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adc4e2421902, replyNumber=0, likeNumber=82, createdTime=2023-02-07, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adc4e2421902, moduleTitle=Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adc4e2421902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831312, encodeId=e2f518313128a, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet子刊：接受激素治疗的成年“变性人”五十年来的死亡趋势报告, objectType=article, longId=217600, objectId=377721e6006d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=377721e6006d, replyNumber=0, likeNumber=76, createdTime=2022-06-21, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=377721e6006d, moduleTitle=Lancet子刊：接受激素治疗的成年“变性人”五十年来的死亡趋势报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=377721e6006d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831555, encodeId=e6be183155573, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：地中海 or 低脂饮食，谁更适合心血管疾病的长期二级预防？, objectType=article, longId=726301, objectId=8edae263013c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8edae263013c, replyNumber=0, likeNumber=74, createdTime=2022-09-17, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8edae263013c, moduleTitle=Lancet：地中海 or 低脂饮食，谁更适合心血管疾病的长期二级预防？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8edae263013c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831206, encodeId=cef518312067d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！, objectType=article, longId=212611, objectId=74632126115d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74632126115d, replyNumber=0, likeNumber=64, createdTime=2021-12-20, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74632126115d, moduleTitle=Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74632126115d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831203, encodeId=6cad1831203bf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：卡培他滨节拍辅助治疗显著改善晚期鼻咽癌患者的存活预后, objectType=article, longId=212477, objectId=7bca2124e7d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bca2124e7d2, replyNumber=0, likeNumber=73, createdTime=2021-09-20, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bca2124e7d2, moduleTitle=Lancet：卡培他滨节拍辅助治疗显著改善晚期鼻咽癌患者的存活预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bca2124e7d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831413, encodeId=8612183141371, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Rheumatology: 雷诺现象患者向系统性硬化症的进展, objectType=article, longId=265001, objectId=fb8c265001b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb8c265001b6, replyNumber=0, likeNumber=0, createdTime=2022-01-26, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb8c265001b6, moduleTitle=Lancet Rheumatology: 雷诺现象患者向系统性硬化症的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb8c265001b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831342, encodeId=a14a1831342d4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet子刊：什么？近十年来，预期寿命反而越来越短了？, objectType=article, longId=219129, objectId=e7e221912971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7e221912971, replyNumber=0, likeNumber=63, createdTime=2022-05-29, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7e221912971, moduleTitle=Lancet子刊：什么？近十年来，预期寿命反而越来越短了？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7e221912971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831293, encodeId=4d35183129301, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, objectType=article, longId=216944, objectId=046e21694492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046e21694492, replyNumber=0, likeNumber=86, createdTime=2021-10-31, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046e21694492, moduleTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046e21694492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831466, encodeId=fd841831466fa, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet 子刊：25岁以下人群的糖尿病死亡率及其趋势——2019年全球疾病负担研究的分析, objectType=article, longId=295438, objectId=57d92954386f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57d92954386f, replyNumber=0, likeNumber=84, createdTime=2022-12-17, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57d92954386f, moduleTitle=Lancet 子刊：25岁以下人群的糖尿病死亡率及其趋势——2019年全球疾病负担研究的分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57d92954386f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831531, encodeId=4b341831531e7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：奥密克戎症状及持续时间已大不相同！多是上呼吸道症状，症状持续时间缩短，但喉咙痛增至70.5%！, objectType=article, longId=723926, objectId=5204e2392635, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5204e2392635, replyNumber=0, likeNumber=71, createdTime=2022-11-13, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5204e2392635, moduleTitle=Lancet：奥密克戎症状及持续时间已大不相同！多是上呼吸道症状，症状持续时间缩短，但喉咙痛增至70.5%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5204e2392635)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831472, encodeId=1a0b18314e2eb, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet子刊：每周一次，“明星药”索马鲁肽治疗肥胖有奇效！, objectType=article, longId=295646, objectId=f581295646db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f581295646db, replyNumber=0, likeNumber=74, createdTime=2022-06-29, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f581295646db, moduleTitle=Lancet子刊：每周一次，“明星药”索马鲁肽治疗肥胖有奇效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f581295646db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831547, encodeId=f1a9183154eb2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Respiratory Medicine：新冠出院一年后，超70%患者仍有后遗症, objectType=article, longId=725423, objectId=6ca9e2542305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ca9e2542305, replyNumber=0, likeNumber=76, createdTime=2022-08-16, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ca9e2542305, moduleTitle=Lancet Respiratory Medicine：新冠出院一年后，超70%患者仍有后遗症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ca9e2542305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831407, encodeId=07bc183140eeb, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：Ianalumab (VAY736) 治疗中重度原发性干燥综合征的效果, objectType=article, longId=221593, objectId=5d39221593f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d39221593f5, replyNumber=0, likeNumber=63, createdTime=2022-07-29, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d39221593f5, moduleTitle=Lancet：Ianalumab (VAY736) 治疗中重度原发性干燥综合征的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d39221593f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831495, encodeId=f7521831495c6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：2020-2021年因新冠预测死亡人数 1820万, objectType=article, longId=300875, objectId=5dfd3008e5d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dfd3008e5d4, replyNumber=0, likeNumber=55, createdTime=2022-04-24, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dfd3008e5d4, moduleTitle=Lancet：2020-2021年因新冠预测死亡人数 1820万, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dfd3008e5d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831316, encodeId=d9571831316df, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Respir Med：从磷酸二酯酶5抑制剂到利奥西呱转换治疗评估, objectType=article, longId=217879, objectId=49a121e879d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49a121e879d0, replyNumber=0, likeNumber=97, createdTime=2021-12-26, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49a121e879d0, moduleTitle=Lancet Respir Med：从磷酸二酯酶5抑制剂到利奥西呱转换治疗评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49a121e879d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831366, encodeId=41f01831366f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Rheumatology: 疑似巨细胞动脉炎患者的血管超声诊断准确性(EUREKA)：一项前瞻性、多中心、非干预性队列研究, objectType=article, longId=219598, objectId=a72a219598f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72a219598f7, replyNumber=0, likeNumber=81, createdTime=2022-05-18, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72a219598f7, moduleTitle=Lancet Rheumatology: 疑似巨细胞动脉炎患者的血管超声诊断准确性(EUREKA)：一项前瞻性、多中心、非干预性队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72a219598f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831310, encodeId=f2a31831310ef, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：EGFR野生型的早期NSCLC患者，免疫治疗获益显著（IMpower010研究）, objectType=article, longId=217564, objectId=4a9821e5642b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9821e5642b, replyNumber=0, likeNumber=72, createdTime=2021-10-04, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9821e5642b, moduleTitle=Lancet：EGFR野生型的早期NSCLC患者，免疫治疗获益显著（IMpower010研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a9821e5642b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831412, encodeId=b596183141283, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Rheumatology: 硬皮病患者为中心的干预网络 (SPIN) 队列中的疼痛水平和相关因素：一项多中心横断面研究, objectType=article, longId=291656, objectId=c8fc291656fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8fc291656fd, replyNumber=0, likeNumber=75, createdTime=2022-07-19, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8fc291656fd, moduleTitle=Lancet Rheumatology: 硬皮病患者为中心的干预网络 (SPIN) 队列中的疼痛水平和相关因素：一项多中心横断面研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8fc291656fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Lancet

2020-05-29

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Respir Med：近期哮喘发作患者感染COVID-19后发生不良结局的风险加大

2022-06-12

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！

2022-05-31

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：新辅助化疗加用尼达尼布对晚期肌肉浸润性膀胱癌患者预后的影响

2023-02-07

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet子刊：接受激素治疗的成年“变性人”五十年来的死亡趋势报告

2022-06-21

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：地中海 or 低脂饮食，谁更适合心血管疾病的长期二级预防？

2022-09-17

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！

2021-12-20

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：卡培他滨节拍辅助治疗显著改善晚期鼻咽癌患者的存活预后

2021-09-20

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Rheumatology: 雷诺现象患者向系统性硬化症的进展

2022-01-26

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet子刊：什么？近十年来，预期寿命反而越来越短了？

2022-05-29

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！

2021-10-31

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet 子刊：25岁以下人群的糖尿病死亡率及其趋势——2019年全球疾病负担研究的分析

2022-12-17

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：奥密克戎症状及持续时间已大不相同！多是上呼吸道症状，症状持续时间缩短，但喉咙痛增至70.5%！

2022-11-13

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet子刊：每周一次，“明星药”索马鲁肽治疗肥胖有奇效！

2022-06-29

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Respiratory Medicine：新冠出院一年后，超70%患者仍有后遗症

2022-08-16

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：Ianalumab (VAY736) 治疗中重度原发性干燥综合征的效果

2022-07-29

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：2020-2021年因新冠预测死亡人数 1820万

2022-04-24

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Respir Med：从磷酸二酯酶5抑制剂到利奥西呱转换治疗评估

2021-12-26

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Rheumatology: 疑似巨细胞动脉炎患者的血管超声诊断准确性(EUREKA)：一项前瞻性、多中心、非干预性队列研究

2022-05-18

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：EGFR野生型的早期NSCLC患者，免疫治疗获益显著（IMpower010研究）

2021-10-04

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Rheumatology: 硬皮病患者为中心的干预网络 (SPIN) 队列中的疼痛水平和相关因素：一项多中心横断面研究

2022-07-19

科室
- - 订阅+
  - 更多科室
工具
服务